Across 8 Trials, Ruxolitinib Cream Shows Favorable Safety in Pediatric AD
A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).
MFN Drug Pricing: Risks to Access, Affordability, and Innovation in Health Care
Adam Colborn, JD, associate vice president of congressional affairs at AMCP, shares insights on the impact of the Most Favored Nation drug pricing order when it comes to access, affordability, and innovations in US health care.
FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC
The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.